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Introduction: Human epidermal growth factor receptor 2 (HER2) is
regarded as a poor prognostic factor in many tumors. Conflicting
data in many literatures were reported about the association between
HER2 and poor prognosis in lung cancer.
Methods: We conducted a meta-analysis of published studies from
1966 to the 12th week of 2010. In absence of significant quality
difference between positive and negative studies, combined hazard
ratios (HRs) and their corresponding 95% confidence intervals (CIs)
were calculated in terms of overall survival.
Results: Forty studies(6135 patients) were included in the analysis.
The pooled data showed that HER2 overexpression was a marker of
poor prognosis in lung cancer. HR was 1.48 (95% CI: 1.22–1.80)
and 3.11 (95% CI: 2.26–4.28) for non-small cell lung cancer
(NSCLC) and small cell lung cancer (SCLC) by immunohistochem-
istry (IHC) assay, respectively. In the NSCLC subgroup analysis of
early stage and ethnicities using IHC and in SCLC subgroup of
extensive stage using IHC, it also showed that HER2 overexpression
determined by IHC was a marker of poor prognosis in NSCLC and
SCLC. In other subgroup of squamous cell carcinoma tested by IHC,
the combined HR was 0.87 (95% CI: 0.61–1.25), indicating that
HER2 overexpression was not a prognostic factor for squamous cell
carcinoma. Finally, in the subgroup analysis of HER2 amplification
status of NSCLC using fluorescence in situ hybridization, we also
found that HER2 amplification determined by fluorescence in situ
hybridization was not significantly related to prognosis.
Conclusions: Although bias could be inevitable, this meta-analysis
suggests that HER2 overexpression is a poor prognostic factor in
lung cancer, especially for SCLC, adenocarcinoma, and early-stage
NSCLC.
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Lung cancer is the leading cause of cancer-related mortalityfor both men and women, with 215,020 new cases and
161,840 deaths expected in 2008.1 Despite improvements in
diagnosis and therapy, the overall 5-year survival is approx-
imately 15%. Several independent prognostic factors have
been identified for predicting survival, including disease
stage (tumor, node, metastasis), performance status, age, sex,
and weight loss.2 Nevertheless, it is controversial that multi-
ple treatments may be used alone or in combination for an
individual, especially for early stage. Therefore, some poten-
tial biologic markers which can predict an individual have
merged, such as epidermal growth factor receptor (EGFR),
K-ras, human epidermal growth factor receptor 2 (HER2),
and thyroid transcription factor-1 (TTF-1).
The EGFR family, including four distinct transmem-
brane receptors (EGFR/erbB-1, HER2/erbB-2, HER3/erbB-3,
and HER4/erbB-4), is expressed in many tumors and re-
garded as a biomarker of aggressive disease and shorter
survival.3 EGFR/erbB-1 has played an important role in lung
cancer for the success of gefitinib. In recent years, the
amplification of HER2 gene in breast cancer has been re-
garded as a poor prognostic factor.4 HER2 overexpression
was also significantly related to diminished survival in lung
caner5; however, conflicting data in the literatures were re-
ported about it.6 If the expression of HER2 indeed is a poor
prognosis in lung cancer, the therapy targeting this pathway
could be very valuable, and the clinical trail about this signal
would be worthy of waiting. In this study, we carried out a
meta-analysis from published studies to quantitatively review
the effects of HER2 in lung cancer.
MATERIALS AND METHODS
Selection Criteria and Search Strategy
For this meta-analysis, we sought data from all pub-
lished full-text articles that reported efficacy survival data in
lung cancer according to HER2 status, except for patients
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treated with trastuzumab. The following criteria for inclusion
were set before collecting articles: (1) the expression or
amplification of HER2 was measured in the primary lung
cancer tissue with immunohistochemistry (IHC) or fluores-
cence in situ hybridization (FISH); (2) comparisons of overall
survival between different expression or amplification of
HER2 in lung cancer; (3) hazard ratios (HRs) for overall
survival according to HER2 status either had to be reported or
could be computed from the data presented; (4) when the
same author or group reported results obtained from the same
patient population in more than one article, the most recent
report or the most informative one was included; and (5)
finally, it must be published as a full article in English or
Chinese language peer-reviewed literature. Two reviewers
(L.L. and X.S.) determined study eligibility independently.
Disagreements were resolved by consensus.
Entries in the PubMed (1966 to the 12th week of 2010),
Embase (1974 to the 12th week of 2010), and the Cochrane
Central Registry of Controlled Trials, Web of Science, and
China Wanfang Data Knowledge Infrastructure (to the 12th
week of 2010) were searched for studies to include in the
present meta-analysis, using the terms “HER2,” “erbB2,”
“HER-2,” “neu,” “p185,” “lung cancer,” and “prognosis.”
The references cited in the identified studies or reviews were
also used to complete the search.
Data Extraction
The following data were independently extracted by
two investigators (L.L. and X.S.) with the standardized data
extraction forms from each study: first author, year of publi-
cation, patient source, number of patients, histology, disease
stage, test method, cutoff value, positive ratio, and survival
data. In addition, disagreements were resolved by a meeting
called by YS.
Methodological Assessment
To assess the quality of these literatures, two reviewers
independently read and scored each study according to the
European Lung Cancer Working Party scale established by
Steels.7 Each item of the score was assessed using an ordinal
scale (possible values 2, 1, and 0). The overall score assessed
several dimensions of methodology, grouped into four main
categories: (1) the scientific design; (2) the description of
the methods used to identify the abnormal of HER2; (3) the
generalizability of the results; and (4) the analysis of the
study data. Each category had a maximal score of 10 points,
and then an overall maximum theoretical score was 40 points.
When an item was not applicable in a study, its theoretical
value was not taken into account. Finally, the scores were
expressed as percentages ranged from 0 to 100%, and better
methodological quality contained higher values.
Definition of Outcomes and Comparisons
The primary outcomes were the overall survival in all
population and then stratified by histologic type, ethnicity,
stage, and test method. The effective value of overall survival
was determined by the combination of HR and 95% confi-
dence interval (CI). If a direct report of HR and 95% CI was
not possible, estimated value was derived indirectly from
other presented data using the methods described by Parmar
et al.8
Statistical Analysis
The statistical heterogeneity within studies was tested
with the 2 based Q-test,9 and lack of heterogeneity across
studies was identified if I2  50%, then the fixed-effects
model was used. Otherwise, it was calculated by the random-
effects model when a significant heterogeneity was found
(I2  50%).10
The combination of the estimated risk was obtained by
calculating a weighted average of the ln HR estimates. The
significance of the pooled HR was determined by the Z test,
and p  0.05 was considered statistically significant. Publi-
cation bias was assessed by Egger’s regression and Begger’s
funnel plot,11 whereas p  0.1 was set as statistically signif-
icant. Statistical computations were all performed with
STATA v10.0 (Stata Corporation, TX). All p values were two
sided.
RESULTS
Trial Flow
Figure 1 depicts results of the literature search. Nine
hundred twenty-four potentially relevant abstracts were found
out, and 40 studies were enrolled into the analysis, containing
major characteristics as in Table 1. Most of the exclusive
abstract were research about cell lines. Eight articles were
updated by new literatures. The insufficient survival data
have been shown in 19 full-text articles and three studies used
enzyme-linked immunosorbent assay (n 1) and quantitative
polymerase chain reaction (n  2) assays (Table 2).
Study Characteristics
From 1994 to 2010, 6135 patients with lung cancer
were included in the meta-analysis, and the median value in
every study was 117.5 (ranged from 42 to 515).
In this analysis, 12 studies (1468 patients, 23.9%) were
conducted in Asian and 28 studies (4667 patients, 76.1%)
were in non-Asian. Thirty-seven of them dealt with non-small
cell lung cancer (NSCLC), whereas small cell lung cancer
(SCLC) was the subject of three studies. Twenty-eight
NSCLC studies (5077 patients) considered more than two
subtypes. Besides, nine studies (659 patients) were about
adenocarcinoma, and three studies (273 patients) were about
squamous cell carcinoma. Seven studies (1738 patients) were
of stage I, 10 studies (2270 patients) were of stages I to II,
four studies (447 patients) were of stages III to IV, and nine
studies were of all stages. Most of the studies investigated
HER2 by IHC (32 studies), and 16 studies followed the
scoring guidelines approved by the Food and Drug Admin-
istration. In addition, the amplification of HER2 was identi-
fied by FISH (seven studies). The positive ratio of HER2 in
individual studies was 25.2%  16.2% by IHC and 20.4% 
18.6% by FISH (Table 1).
Thirteen studies investigated HER2 as an indicator of
poor prognosis, and the other 27 studies showed no signifi-
cant impact on overall survival.
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Assessment of Study Quality
Between the two reviewers on overall quality score, the
Spearman rank correlation coefficient for agreement was 0.96
in all included studies.
Concerning all included studies, the median value of
global quality score was 55.0% (31.8–79.8%), and the labo-
ratory methodology had the highest value (a median value 5.7
of 10). In the systematic analysis, no statistically significant
difference of quality was found between positive and nega-
tive studies (median of 54.5% versus 55.3%, p  0.82).
Meanwhile, no significant quality difference was found be-
tween IHC and FISH (median of 55.3% versus 54.8%, p 
0.21) and between Asian and non-Asian (median of 51.3%
versus 55.3%, p  0.38) (Table 3).
Finally, no significant correlation was shown between
global quality scores and the number of patients enrolled in
the studies or the publication date of the articles (data not
shown).
Test of Heterogeneity
The heterogeneity was analyzed for all included studies
(n  40) between HER2 and the prognosis of lung cancer,
with the 2 test (2  108.66, p  0.00 for NSCLC by IHC;
2  14.54, p  0.02 for NSCLC by FISH, 2  6.66, p 
0.04 for SCLC by IHC) in a random-effects model. Mean-
while, the heterogeneity of included studies was also 71.5%,
58.7%, and 70.0% with the I2 value, respectively. As for the
subgroup analysis about squamous cell carcinoma by IHC
assay, heterogeneity was not detected between HER2 status
and prognosis of NSCLC. When the subset analyses (ethnic-
ity, stage, and histology) were performed, the statistical
heterogeneity was reduced (Table 4).
Meta-Analysis
The results of each meta-analysis were presented in
Table 4 and Figures 2 to 7. The overall 40 studies were
systematic analyzed, with the combined HR 1.48 (95% CI:
1.22–1.80) and 3.11 (95% CI: 2.26–4.28) for NSCLC (Fig-
ure 2) and SCLC (Figure 3A) by IHC, respectively. There-
fore, HER2 overexpression was associated with poor prog-
nosis in lung cancer.
We also conducted subgroup analyses about ethnicity,
histologic type, and stage. Because HER2 amplification de-
termined by FISH was available in only one study (Soh et
al.63), we excluded it from the subgroup analysis of adeno-
carcinoma. Similarly, one study (Pelosi et al.6) was excluded
from the subgroup analysis of stages I and I to II NSCLC.
Additionally, another study using IHC (Calikusu et al.66) was
not eligible for the subgroup analysis of stages III to IV
NSCLC tested by FISH.
In NSCLC tested by IHC, the combined HR was 1.51
(95% CI: 1.18–1.95), 1.41 (95% CI: 1.03–1.94), 1.95 (95%
CI: 1.56–2.43), 1.57 (95% CI: 1.30–1.90), and 1.39 (95% CI:
1.19–1.63) for non-Asian, Asian, adenocarcinoma (Figure
4A), stage I (Figure 5A), and stages I to II (Figure 5B),
respectively. In addition, the combined HR was 3.00 (95%
CI: 2.24–4.02) in extensive-stage SCLC using IHC (Figure
3B). It also showed that HER2 overexpression determined by
IHC was a marker of poor prognosis in NSCLC and SCLC.
Meanwhile, when we restricted the analysis to squamous cell
carcinoma tested by IHC, the combined HR was 0.87 (95%
CI: 0.61–1.25), indicating that HER2 overexpression was not
a prognostic factor for squamous cell carcinoma (Figure 4B).
Finally, in the subgroup analysis of HER2 amplification
status of NSCLC using FISH, the combined HR was 1.14
(95% CI: 0.72–1.83) and 0.89 (95% CI: 0.63–1.27) for all
available patients (Figure 6) and stages III to IV (Figure 7),
respectively, suggesting HER2 amplification determined by
FISH was not significantly related to prognosis of NSCLC.
Publication Bias
The Egger’s test and Begg’s funnel plot were applied
for detecting publication bias in the meta-analysis. In all
FIGURE 1. Studies of the associations between
human epidermal growth factor receptor 2
(HER2) and prognosis of lung cancer: literature
search and selection of articles.
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included studies, no funnel plot asymmetry was found, with
p  0.88 in the Egger’s test and p  0.50 in the Begg’s test
(Figure 8). So, there is no evident publication bias in the
analysis.
DISCUSSION
The HER2 oncogene, known as c-erbB-2, HER2/neu,
or p185neu, located in the chromosomal region 17q11.2-
q12, was reported firstly in 1984.72 The possible role of
HER2 is that increasing cell proliferation, angiogenesis,
and metastasis and decreasing apoptosis. The dimeri-
zation HER2 with an activated EGFR molecule can
activate the downstream signaling pathway.3 HER2 is
expressed in the breast,72 ovarian,73 osteosarcoma,74 and lung
cancer.5,6,19,21,27,28,30,35–37,40,41,43–48,50,51,53–56,58,59,61–66,69–71,75–77
The most extensive study of HER2 was performed in breast
cancer, which links to a potentially poor prognosis.4
Although two meta-analyses had been reported before
2005, there was overlapping patient groups78 or ignoring
many valuable studies because of only survival rates com-
bined.79 Consequently, as regards prognostic value of HER2
in lung cancer, little information has been available relatively.
Recently, some large sample studies were carried out and
some previous studies were updated. Moreover, neratinib
(HKI-272), an irreversible dual inhibitor of EGFR and HER2,
has promising activity in both breast cancer and NSCLC with
an acceptable safety profile.80 Therefore, the actual evalua-
tion of HER2 in the prognosis of lung cancer requires a more
accurate systematic analysis.
This meta-analysis shows that HER2 overexpression
determined by IHC is significantly associated with a poor
prognosis in lung cancer. In SCLC, when we combined HR in
all stages or extensive stage only from the included studies,
both of the analysis suggested that HER2 was a poor prog-
TABLE 1. Characteristics of Some Studies Excluded from the Meta-Analysis
Authors Year S. of Pts. NP Histology (Number) Stage Method Cutoff Positive (%) Comments
Mackinnon et al.12 1997 UK 162 AC(162) NA IHC 10% 18.5 NS
Visscher et al.13 1997 US 31 AC(31) I–IV IHC 50% 71.0 NS
Fontanini et al.14 1998 IT 195 AC(66), SC(116), etc. I–IIIa IHC 5% 61 NS, p  0.62
Graziano et al.15 1998 US 61 NA IIIa IHC 25% 16.4 NS, p  0.62
Greatens et al.16 1998 US 101 AC(51), SC(44), etc. I–IV IHC 2 14.9 NS
Nemunaitis et al.17 1998 US 103 AC(95), etc. I–IV IHC 2 30.1 NS, p  0.78
Fu et al.18 1999 CN 158 AC(53), SC(63), etc. I–IIIb IHC NA 56.3 NS, p  0.18
Cantero et al.19 2000 Spain 102 AC(30), SC(64), etc. I–IIIa ELISA 350 U/mg 20 S, p  0.03.
Overexpression indicated
a poor prognosis
Schneider et al.20 2000 DE/US 103 AC(37), SC(49), etc. I–IIIa IHC 2 54.4 S, p  0.05.
Overexpression indicated
a poor prognosis,
especially for AC(p 
0.01)
Brabender et al.21 2001 US/DE 83 AC(32), SC(39), etc. I–IIIa qPCR T:N 1.8 34.9 S, p  0.04.
Overexpression indicated
a poor prognosis
Carbognani et al.22 2002 IT 78 AC(17), SC(49), etc. I–IIIa IHC 20% 17.9 NS, p  0.58
Hilbe et al.23 2003 Austria 79 AC(37), SC(37), etc. I–IV IHC 15.7% 37 NS
Kanematsu et al.24 2003 JP 36 SC(14), non-SC(22) I–IV IHC 50% 27.8 NS, p  0.23
Brattstrom et al.25 2004 Sweden 53 AC(22), SC(22), etc. NA IHC 2 15 NS, p  0.10
Onn et al.26 2004 US 111 AC(36), SC(40), etc. I IHC 2 17.1 NS
Bozcuk et al.27 2005 Turkey 70 AC(22), SC(43), etc. I–III IHC 2 42 NS, p  0.30
Vallbohmer et al.28 2006 US/DE 90 AC(33), SC(42), etc. I–IIIa qPCR 14.21 14.4 NS, p  0.09
Tsutsumida et al.29 2007 JP 185 AC(185) I–III IHC 25% 27.3 NS in small-sized lung
AC(3 cm)
Parra et al.30 2008 Brazil 52 AC(52) I–IV IHC 27% 88.5 S, p  0.04.
Overexpression indicated
a poor prognosis
Tiseo et al.31 2009 IT 91 AC(70), etc. III–IV FISH 4 copies in
40% cells
19 NS, p  0.77
Varella-Garcia et al.32 2009 JP 44 AC(38), non-AC(6) I–IV FISH 4 copies in
40% cells
53 NS, p  0.67, from the
day of initiating gefitinib
treatment
Xu et al.33 2009 CN 84 AC(61), non-AC(23) IIIb–IV IHC 2 45.2 NS
S. of Pts., source of patients; UK, the United Kingdom; US, the United States; IT, Italy; CN, China; DE, Germany; JP, Japan; NP, number of patients; AC, adenocarcinoma;
SC, squamous cell carcinoma; NA, not available; IHC, immunohistochemistry; ELISA, enzyme-linked immunosorbent assay; qPCR, quantitative polymerase chain reaction; FISH,
fluorescence in situ hybridization; NS, nonsignificant; S, significant; HER2, human epidermal growth factor receptor 2.
Journal of Thoracic Oncology • Volume 5, Number 12, December 2010 Role of HER2
Copyright © 2010 by the International Association for the Study of Lung Cancer 1925
TABLE 2. Characteristics of Studies Included in the Meta-Analysis
Authors Year S. of Pts. NP Histology (Number) Stage Method Cutoff
Positive
(%) HR Est. HR 95% CI
Volm et al.34 1992 DE 81 SC(81) I–IV IHC 25% 35.8 IPD 0.87 0.55–1.37
Kern et al.5 1994 US 44 AC(44) I–IV IHC NA 34 HR  CI 2.60 1.20–3.50
Tateishi et al.35 1994 JP 119 AC(119) I–IV IHC NA 28 Sur. Curve 2.43 1.40–4.20
Giatromanolaki et al.36 1996 Greece 107 AC(38), SC(69) I–II IHC 65% 18.7 HR  CI 1.25 0.64–2.43
Pfeiffer et al.37 1996 Denmark 186 AC(59), SC(102), etc. I–II IHC 2 26 HR  CI 0.89 0.56–1.41
Pastorino et al.38 1997 IT 515 AC(217), SC(252), etc. I IHC 10% 4 HR  CI 1.05 0.58–1.92
Yu et al.39 1997 CN 116 AC(69), SC(47)AC I–IIIa IHC NA 36.8 HR  CI 2.15 1.15–4.03
3.02 1.21–7.55
Hsieh et al.40 1998 CN 42 AC(42) I IHC 40% 50 Sur. Curve 6.58 1.78–24.32
Kim et al.41 1998 Korea 238 AC(35), SC(203) I–IV IHC 50% 40.2 HR  CI 1.30 0.80–1.90
Kwiatkowski et al.42 1998 US 243 AC(142), SC(62), etc. I IHC 2 43 Logrank  n
events
1.05 0.67–1.64
D’Amico et al.43 1999 US 408 NA I IHC 50% 25 HR  CI 1.43 1.07–1.90
Moldvay et al.44 2000 France 227 AC(95) I–IV IHC NA 20.6 Logrank  n
events
0.94 0.51–1.70
SC(132) 0.69 0.32–1.48
Cox et al.45 2001 US 167 AC(50), SC(103), etc. I–IIIa IHC 2 1.8 HR  CI 1.50 0.37–6.10
Korrapati et al.46 2001 US 239 AC(81), SC(95), etc. I–II IHC 2 18 Sur. Curve 1.11 0.70–1.76
Liao et al.47 2001 CN 127 AC(80), SC(31), etc. I–IIIa IHC 10% 46.7 Logrank  n
events
1.28 0.79–2.08
Shou et al.48 2001 JP 111 AC(80), SC(37), etc. I–III IHC Mean–SD 78.2 Sur. Curve 0.70 0.35–1.38
Haque et al.49 2002 US 57 AC(28), SC(29) I–III IHC 50% 17 IPD 0.77 0.32–1.83
Han et al.50 2002 US 85 AC(46), SC(25), etc. I IHC NA 29 Sur. Curve 2.98 1.54–5.76
Hirsch et al.51 2002 US 187 AC(95), SC(113), etc. I–IIIa IHC 2 18 Sur. Curve 1.38 0.68–2.77
Piyathilake et al.52 2002 UK 60 SC(60) I–IV IHC Median NA Sur. Curve 1.19 0.49–2.85
Selvaggi et al.53 2002 IT 130 AC(48), SC(60), etc. I–IIIa IHC 5% 12 HR  CI 2.94 1.62–5.34
Nakamura et al.54 2003 JP 50 AC(34), SC(15), etc. I, IIB, III IHC 2 26 Sur. Curve 2.22 0.64–7.67
FISH HER2/C173 44 0.94 0.17–5.14
Tan et al.55 2003 US 131 AC(82), SC(44), etc. I–IIIa FISH HER2/C172.0 5.3 HR  CI 2.59 1.03–6.54
Au et al.56 2004 Canada 284 AC(93), SC(123), etc. NA IHC 2 2.5 Sur. Curve 13.22 5.44–32.12
Saad et al.57 2004 US 100 AC(100) I IHC 10% 28 Sur. Curve 2.41 1.52–3.82
Cheng et al.58 2005 JP 312 AC(175), SC(137) I–IV IHC 2 11.2 Sur. Curve 0.66 0.35–1.25
Meert et al.59 2005 Belgium 129 AC(54), SC(63), etc. I–IV IHC 2 22 Sur. Curve 1.69 0.89–3.20
Pelosi et al.6 2005 IT 345 AC(173), SC(159), etc. I FISH HER2/C174 1.4 Sur. Curve 2.39 0.56–10.30
Cappuzzo et al.60 2005 IT 102 AC(54), SC(26) III–IV FISH 4 copies in
40% cells
22.8 Sur. Curve 0.73 0.39–1.38
Szelachowska et al.61 2006 Poland 64 AC(23), etc. I–III IHC 2 10.9 Sur. Curve 0.66 0.23–1.91
Hirsch et al.62 2007 IT/US 204 AC(99), SC(26), etc. III–IV FISH Polysomy 40% 25 Logrank  n
events
0.69 0.42–1.13
Soh et al.63 2007 JP 74 AC(60), etc. NA FISH 4 copies in
40% cells
43.2 HR  CI 0.75 0.43–1.29
IHC 2 34 0.61 0.24–1.57
Kuyama et al.64 2008 JP 68 AC(28), SC(30), etc. IIIa–IIIb FISH HER2/C17
median value
0.93 HR  CI 2.57 1.12–5.90
Ludovini et al.65 2008 IT 132 AC(49), SC(62), etc. I–III IHC 2 25 HR  CI 0.96 0.50–1.84
Calikusu et al.66 2009 Turkey 73 AC(27), SC(34), etc. IIIb–IV IHC 2 28.2 HR  CI 3.10 2.21–4.67
Kashihara et al.67 2009 JP 104 AC(66), SC(38) NA IHC 2 7.5 HR  CI 1.91 0.82–4.47
Toh et al.68 2010 Singapore 107 AC(107) I–IV IHC Any staining 24.3 HR  CI 1.47 0.87–2.50
Micke et al.69 2001 DE 107 SCLC LS,ES IHC 2 13 HR  CI 2.16 1.16–4.00
Potti et al.70 2002 US 193 SCLC ES IHC 2 29.5 Sur. Curve 4.61 2.97–7.14
Canoz et al.71 2006 Turkey 67 SCLC LS,ES IHC 2 17.9 Sur. Curve 1.82 0.90–3.67
S. of Pts., source of patients; US, the United States; DE, Germany; JP, Japan; IT, Italy; CN, China; NP, number of patients; AC, adenocarcinoma; SC, squamous cell carcinoma;
SCLC, small cell lung cancer; LS, Limited stage; ES, extensive stage; NA, not available; IHC, immunohistochemistry; FISH, fluorescence in situ hybridization; T:N, tumor compared
with paired normal lung tissue; SD, standard deviation; C17, chromosome 17; HR Est., HR estimation; HR, hazard ratio; Sur. Curve, survival curve; CI, confidence interval; HER2,
human epidermal growth factor receptor 2.
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nostic factor in SCLC. As for NSCLC, we found that the
association between HER2 and poor prognosis was signifi-
cant in adenocacinoma, not squamous cell carcinoma in the
histologic type analysis. When stratified analysis was con-
ducted about different stages of NSCLC, the association was
also found in stages I and I to II, indicating that HER2 could
probably predict worse prognosis in early-stage NSCLC.
About test method, we found that the association was signif-
icant by IHC, not by FISH, showing that HER2 overexpres-
sion, not amplification, might be a marker of poor prognosis.
Our results were consistent with two previous meta-analyses
published in 200378 and 2005,79 and we all found the signif-
icant association between HER2 overexpression and poor
prognosis in NSCLC. Nevertheless, we improved the sys-
temic analysis by comprehensive search strategy and recent
updated studies. We also conducted analysis for SCLC and
stratified analysis for ethnicity, histologic type, stage, and test
method in NSCLC. So, we got more information between
HER2 and prognosis of lung cancer. Additionally, two inves-
tigators independently determined study eligibility, extracted
data, and assessed quality of study, so a better quality control
was performed in our analysis.
Several technical issues must be mentioned in our
meta-analysis. Significant heterogeneity was found in this
meta-analysis (I2 71.5% and 70.0% for NSCLC and SCLC,
respectively). When the analysis was limited to different
ethnicity, stage, and histology, the heterogeneity was re-
duced. Furthermore, when it was restricted to studies with
squamous cell carcinoma, heterogeneity was not detected.
Therefore, the most important factor explaining the hetero-
TABLE 3. Results of the Methodological Assessment by the European Lung Cancer Working Party Score
Nb Global Score (%) Designa
Laboratory
Methodologya Generalizabilitya Results Analysisa
All studies 40 55.0 5.4 5.7 5.3 5.3
Positive 13 54.5 5.3 5.4 5.5 5.3
Negative 27 55.3 5.4 6.4 5.1 5.4
p 0.82 0.87 0.52 0.09 0.88
IHC 35 55.3 5.7 6.3 4.5 5.3
FISH 5 54.8 5.0 5.0 5.3 5.1
p 0.21 0.21 0.09 0.15 0.79
Asian 12 51.3 5.4 5.2 4.8 4.9
Non-Asian 28 55.3 5.4 5.9 5.5 5.4
p 0.38 0.78 0.25 0.22 0.62
Score distributions are summarized by the median values.
a Score out of 10.
Nb, number of studies; positive, studies identifying HER2 overexpression as a significant poor prognostic factor for survival; negative, studies reporting nonsignificant results
or identifying HER2 overexpression as a better prognostic factor for survival; IHC, immunohistochemistry; FISH, fluorescence in situ hybridization; HER2, human epidermal growth
factor receptor 2.
TABLE 4. Meta-Analysis: HR Value in Lung Cancer Subgroups According to Ethnicity, Histology, Stage, and Methods of
Detecting HER2
Nb
No. of
Patients HRs (95% CI)
Heterogeneity Test
2 I2 p
HER2 in NSCLC
IHC 32 4912 1.48 (1.22–1.80) 108.66 71.5% 0.000
Non-Asian 21 3518 1.51 (1.18–1.95) 83.52 76.1% 0.000
Non-Asian (Positive ratio 5%) 18 2552 1.42 (1.12–1.80) 58.88 71.1% 0.000
Asian 11 1394 1.41 (1.03–1.94) 24.65 59.4% 0.006
AC 8 599 1.95 (1.56–2.43) 17.51 60.0% 0.014
SC 3 273 0.87 (0.61–1.25) 0.84 0.0% 0.658
Stage I 6 1393 1.57 (1.30–1.90) 16.81 70.3% 0.005
Stages I–II 9 1925 1.39 (1.19–1.63) 23.03 65.3% 0.003
FISH 7 974 1.14 (0.72–1.83) 14.54 58.7% 0.024
Non-Asian 4 782 1.12 (0.59–2.15) 8.28 63.8% 0.041
Asian 3 192 1.23 (0.50–3.05) 5.90 66.1% 0.052
Stage III–IV 3 374 0.89 (0.63–1.27) 7.65 73.9% 0.022
HER2 in SCLC 367 3.11 (2.26–4.28) 6.66 70.0% 0.036
Extensive stage (IHC) 3 304 3.00 (2.24–4.02) 6.62 69.8% 0.036
Nb, number of studies; HRs, hazard ratios; CI, confidence interval; NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer; AC, adenocarcinoma; SC, squamous cell
carcinoma; IHC, immunohistochemistry; FISH, fluorescence in situ hybridization; HER2, human epidermal growth factor receptor 2.
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FIGURE 2. Meta-analysis of the
evaluable studies assessing human
epidermal growth factor receptor 2
(HER2) by immunohistochemistry
(IHC) in non-small cell lung cancer
(NSCLC) and subgroup analysis of
non-Asian and Asian.
FIGURE 3. Meta-analysis of the evaluable studies
assessing human epidermal growth factor recep-
tor 2 (HER2) by immunohistochemistry (IHC) in
small cell lung cancer (SCLC) (A) and subgroup
analysis of extensive stage (B).
FIGURE 4. Meta-analysis of the evaluable studies
assessing human epidermal growth factor receptor
2 (HER2) by immunohistochemistry (IHC) in adeno-
carcinoma (A) and squamous cell carcinoma (B).
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geneity was different histologic types and stages. We have
also seen that the heterogeneity was magnified when the
subgroup analysis included stages III to IV NSCLC. Radical
surgery cannot be done in this stage, so there were some
differences between individuals in obtaining tumor samples.
In addition, the application of detection methods and exper-
imental conditions are important sources of heterogeneity. In
particular, different primary antibodies, different staining
techniques, and different cutoff values may affect the results
of IHC. So, when we excluded three studies (Au et al.,56
Pastorino et al.,38 and Cox et al.45) from the analysis of
non-Asian NSCLC by IHC because of the low positive ratio,
the heterogeneity was also reduced. Nevertheless, there is no
definitive explanation for the heterogeneity.
Furthermore, caution should be taken into account
about biases. First, publication bias is a major concern in all
forms of meta-analysis,11 as published studies are often pos-
itive and so the omission of unpublished studies may lead to
exaggeration of the pooled HR. Our analysis included only
published articles until March 2010, so it is possible that
some unpublished and related articles were excluded. Al-
though in the analysis obtained summary statistics did not
support publication bias, language bias could not be com-
FIGURE 8. Contour-enhanced funnel plot of the 40 evalu-
able studies assessing human epidermal growth factor recep-
tor 2 (HER2) in lung cancer.
FIGURE 5. Meta-analysis of the evaluable studies
assessing human epidermal growth factor recep-
tor 2 (HER2) by immunohistochemistry (IHC) in
early-stage non-small cell lung cancer (NSCLC).
Stage I (A) and stages I to II (B).
FIGURE 6. Meta-analysis of the evaluable studies assessing
human epidermal growth factor receptor 2 (HER2) by fluores-
cence in situ hybridization (FISH) in non-small cell lung can-
cer (NSCLC) and subgroup analysis of non-Asian and Asian.
FIGURE 7. Meta-analysis of the evaluable studies assessing
human epidermal growth factor receptor 2 (HER2) by fluores-
cence in situ hybridization (FISH) in stages III to IV.
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pletely avoided, because of restricted only in English and
Chinese. Moreover, a systematic review process with rigid
inclusion criteria was adopted in ascertaining studies, thereby
reducing selection bias.81 We also compare the clinicopath-
ologic features between studies reporting significant and
nonsignificant difference; no significant differences were
found (data not shown). Then, it boosts our confidence in the
analysis. We also conducted methodological assessment to
avoid selection bias, and no significant difference was found
between positive and negative studies. Despite that, however,
19 studies were excluded from the analysis because of the
insufficient survival data, in which 17 of 19 of them have got
nonsignificant results. Additionally, only three studies used
enzyme-linked immunosorbent assay (n 1) and quantitative
polymerase chain reaction (n  2) assay, and these three
studies have been excluded from the current analysis to
increase and emphasize the importance of the findings. Con-
sequently, selection bias might occur. Finally, most of our
analysis was based on literatures and not individual patient
data. Only two studies34,49 (138 patients) reported IPD in
these published articles. So, the multivariate analyses cannot
be performed, and it cannot be exactly known whether HER2
expression is a prognostic factor, independently of known
clinical factors, such as stages (tumor, node, metastasis),
differentiation, age, sex, and weight loss. Therefore, the
results must be interpreted cautiously, because the IPD-based
analysis provide the least bias and is more reliable than
literature-based meta-analysis.82
Recently, mutations in the HER2 kinase domain, ap-
proximately in 2 to 4% of lung adenocarcinomas, are re-
garded as a more important biomarker rather than amplifica-
tion and overexpression in lung cancer. The majority of the
HER2 mutations in NSCLC are duplications or in-frame
insertions in exon 20.83,84 The presence of the altered HER2
protein characterizes a subgroup of NSCLC, which is ad-
dicted to HER2 pathway. Therefore, HER2 mutation offered
a potential target for future anticancer therapy. PF00299804,
an irreversible pan-HER inhibitor, can effectively inhibit both
the wild-type and mutated HER2.85 In addition, rapamycin
can block Akt/mTOR pathway, which was potentially acti-
vated by HER2 mutations.86 Besides, although trastuzumab
failed to demonstrate clinical benefit in NSCLC,87 a partial
response has been detected,88 and the status of HER2 muta-
tion on protocol ECOG-2598 has been worth the wait. More
importantly, both BIBW 299289 and HKI-272,90 irreversible
dual EGFR/HER2 inhibitors, have been sensitive to an erlo-
tinib-resistant NSCLC cell line NCI-H1781 harboring the
HER2 mutation. De Greve et al.91 reported preliminary re-
sults about BIBW 2992 as a potential new treatment option
for patients with prior chemotherapy/target therapy (up to five
lines) failure. Three of three pretreated patients with NSCLC,
with HER2 mutations in exon 20, resulted in significantly
subjective and objective benefit. Nevertheless, despite all
these findings, no final conclusions have been reached about
HER2 mutation and exact HER2-targeted therapy.
In conclusion, in this systematic analysis, we found that
HER2 overexpression determined by IHC, not amplification,
was associated with poor prognosis in lung cancer, especially
in SCLC, adenocarcinoma, and early-stage NSCLC. Our
meta-analysis also suggested that HER2 be a detrimental
protein for lung cancer, and then patients with SCLC or
early-stage adenocarcinoma and HER2 overexpression prob-
ably should take aggressive treatment. Nonetheless, our re-
sults should be confirmed by a well-designed prospective
study.
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